Cargando…

A multistakeholder approach to innovations in NAFLD care

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally and requires multidisciplinary care. Here, we report key findings of a NAFLD care workshop, address knowledge gaps and highlight a path to optimise healthcare resource use, to improve outcomes in patients with steatotic liver dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schattenberg, Jörn M., Allen, Alina M., Jarvis, Helen, Zelber-Sagi, Shira, Cusi, Ken, Dillon, John F., Caussy, Cyrielle, Francque, Sven M., Younossi, Zobair, Alkhouri, Naim, Lazarus, Jeffrey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810711/ https://www.ncbi.nlm.nih.gov/pubmed/36596859 http://dx.doi.org/10.1038/s43856-022-00228-y

Ejemplares similares

Integrating social nutrition principles into the treatment of steatotic liver disease
por: Ivancovsky-Wajcman, Dana, et al.
Publicado: (2023)

Refining imaging tools to detect advanced fibrosis: could liver surface nodularity address an unmet need in the NAFLD epidemic?
por: Schattenberg, Jörn M., et al.
Publicado: (2022)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

NAFLD in the Elderly
por: Alqahtani, Saleh A, et al.
Publicado: (2021)

Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data
por: Paik, James M., et al.
Publicado: (2021)

The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?
por: Lazarus, Jeffrey V., et al.
Publicado: (2021)

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
por: Paik, James M., et al.
Publicado: (2023)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

It is time to expand the fatty liver disease community of practice
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

COVID-19, childhood obesity, and NAFLD: colliding pandemics
por: Moore, J Bernadette
Publicado: (2022)

Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
por: Lazarus, Jeffrey V., et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
por: Golabi, Pegah, et al.
Publicado: (2016)

Obésité et infection par la COVID-19 : une liaison dangereuse
por: Caussy, Cyrielle
Publicado: (2021)

The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2016)

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
por: Vieira Barbosa, Joana, et al.
Publicado: (2021)

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example
por: Page, Sandra, et al.
Publicado: (2013)

Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD
por: Mehta, Rohini, et al.
Publicado: (2013)

Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations
por: Zelber-Sagi, Shira, et al.
Publicado: (2021)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)
por: Alkhouri, Naim, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Dietary strategies in non‐alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review
por: Hadefi, Alia, et al.
Publicado: (2023)

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017)

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
por: Younossi, Zobair M., et al.
Publicado: (2021)

Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
por: Baranova, Ancha, et al.
Publicado: (2013)

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Nier, Anika, et al.
Publicado: (2020)

NAFLD in type 1 diabetes: overrated or underappreciated?
por: Mertens, Jonathan, et al.
Publicado: (2021)

Inclusive innovation in telehealth
por: Noel, Kimberly, et al.
Publicado: (2020)

Innovations to improve the efficiency of phase II IBD clinical trials
por: Noor, Nurulamin M., et al.
Publicado: (2023)

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa
por: Manzano‐Nunez, Ramiro, et al.
Publicado: (2023)

COVID-19, structural racism, and migrant health in Canada
por: Tuyisenge, Germaine, et al.
Publicado: (2021)

Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Future of the drug label: Perspectives from a multistakeholder dialogue
por: Gispen‐de Wied, Christine C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_81k4c43gcfj49hs7ajr6oh51rj